Differential proteoglycan and hyaluronan distribution in calcified aortic valves
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background While the prevalence of calcified aortic valve disease continues to rise and no pharmacological treatments exist, little is known regarding the pathogenesis of the disease. Proteoglycans and the glycosaminoglycan hyaluronan are involved in calcification in arteriosclerosis and their characterization in calcified aortic valves may lend insight into the pathogenesis of the disease. Methods 14 calcified aortic valves removed during valve replacement surgery were immunohistochemically stained for the proteoglycans (PGs) decorin, biglycan, and versican, as well as the glycosaminoglycan hyaluronan. Staining intensity was evaluated in the following regions of interest: center of calcified nodule, edge of nodule, tissue directly surrounding nodule; center and tissue surrounding small “prenodules”; and fibrosa layer of normal regions of the leaflet distanced from the nodule. Results Decorin, biglycan, and versican, as well as hyaluronan, were abundantly present immediately surrounding the calcified nodules, but minimally within the nodule itself. Expression of decorin and biglycan in and surrounding prenodules was greater than in the edge and center regions of mature nodules. The levels of expression of the PGs and hyaluronan were highly correlated with one another in the different regions of the valve. Conclusions The three PGs and hyaluronan demonstrated distinctive localization relative to nodules within calcified aortic valves, where they likely mediate lipid retention, cell proliferation, and extracellular matrix remodeling, and motivate further study. Comparisons between expression of these components in mature nodules and prenodules suggest distinct roles for these components in nodule progression, especially in the tissues surrounding the nodules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 2×
“CAVD is associated with aging [1], male gender [2], and metabolic syndrome [3], and is only treatable by surgical replacement of the stenotic valve with a mechanical, bioprosthetic or biological valve [4].”
BackgroundIntensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146 · cited 1×
“ability of these lipid-lowering drugs to reduce valve calcification in vitro [6,7] and in animal models [8–10], but, unfortunately, that promise has not translated to a significant improvement in prospective clinical trials [11–13].”
BackgroundO’Brien, K. D., Reichenbach, D. D., Marcovina, S. M., Kuusisto, J., Alpers, C. E., & Otto, C. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.4.523 · Cited by 560
Distinct interaction of versican/PG-M with hyaluronan and link protein
Matsumoto, K., Shionyu, M., Go, M., Shimizu, K., Shinomura, T., Kimata, K., & Watanabe, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305060200 · Cited by 153
Cited by
Myocardial Extracellular Matrix: An Ever-Changing and Diverse Entity
Rienks, M., Papageorgiou, A.-P., Frangogiannis, N. G., & Heymans, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.302533 · Cited by 366
Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms
Miller, J. D., Weiss, R. M., & Heistad, D. D. (2011) · Circulation Research · doi:10.1161/circresaha.110.234138 · Cited by 323
Calcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Chen, J.-H., & Simmons, C. A. (2011) · Circulation Research · doi:10.1161/circresaha.110.234237 · Cited by 289
Schlotter, F., Halu, A., Goto, S., Blaser, M. C., Body, S. C., Lee, L. H., Higashi, H., DeLaughter, D. M., Hutcheson, J. D., Vyas, P., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032291 · Cited by 256
Metadata
- Authors
- Stephens, E. H., Saltarrelli, J. G., Baggett, L. S., Nandi, I., Kuo, J. J., Davis, A. R., Olmsted-Davis, E. A., Reardon, M. J., Morrisett, J. D., & Grande-Allen, K. J.
- Venue
- Cardiovascular Pathology
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 20
- Issue
- 6
- Pages
- 334-342
- ISSN
- 1054-8807 (ISSN-L)
- OpenAlex
- W2150058785
- Cited by
- 78
- References
- 5
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.